Evaluation of MALDI-TOF mass spectrometry for the identification of medically-important yeasts in the clinical laboratories of Dijon and Lille hospitals

Medical Mycology

Volumn 51, Issue 1, 2013, Pages 25-32

  Sendid, Boualem ^a,b   Ducoroy, Patrick ^c   François, Nadine ^a   Lucchi, Geraldine ^c   Spinali, Sebastien ^d   Vagner, Odile ^e   Damiens, Sebastien ^a,b   Bonnin, Alain ^e,f   Poulain, Daniel ^a,b   Dalle, Frederic ^e,f  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE LILLE   (France)

^c HÔPITAL DU BOCAGE   (France)

^d Centre de Biologie pathologie Institut de Microbiologie   (France)

^e Plateau Technique de Biologie   (France)

^f UNIV BOURGOGNE FRANCHE COMTÉ   (France)

Author keywords

MALDI TOF mass spectrometry; Uncommon yeasts; Yeast identification

Indexed keywords

INTERNAL TRANSCRIBED SPACER; RIBOSOME DNA;

ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA FAMATA; CANDIDA INCONSPICUAL; CANDIDA LAMBICA; CANDIDA MAGNOLIAE; CANDIDA METAPSILOSIS; CANDIDA NORVEGENSIS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CLINICAL LABORATORY; GEOTRICHUM; HOSPITAL; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; PROSPECTIVE STUDY; TRICHOSPORON; YEAST;

EID: 84870955719     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2012.693631     Document Type: Article

References (48)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: A persistent public health problem. Clin Microbiol Rev 2007; 20: 133- 163.
2. Groll AH, Walsh TJ. Uncommon opportunistic fungi: New nosocomial threats. Clin Microbiol Infect 2001; 7: 8-24.
3. Nucci M, Marr KA. Emerging fungal diseases. C lin Infect Dis 2005; 41: 521-526.
4. Atkinson BJ, Lewis RE, Kontoyiannis DP. Candida lusitaniae fungemia in cancer patients: Risk factors for amphotericin B failure and outcome. Med Mycol 2008; 46: 541-546.
5. Chen SC, Marriott D, Playford EG, et a l. Candidaemia with uncommon Candida species: Predisposing factors, outcome, antifungal susceptibility, and implications for management. Clin Microbiol Infect 2009; 15: 662-669.
6. Girmenia C, Pagano L, Martino B, et a l. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: A retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005; 43: 1818- 1828.
7. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36: 1-53.
8. Ruan SY, Huang YT, Chu CC, Yu CJ, Hsueh PR. C andida glabrata fungaemia in a tertiary centre in Taiwan: Antifungal susceptibility and outcomes. Int J Antimicrob Agents 2009; 34: 236-239.
9. Cuenca-Estrella M, Gomez-Lopez A, Isla G, et a l. Prevalence of Candida bracarensis and Candida nivariensis in a Spanish collection of yeasts: Comparison of results from a reference centre and from a population-based surveillance study of candidemia. Med Mycol 2011; 49: 525-529.
10. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: Review of the literature. Rev Iberoam Micol 2003; 20: 121-136.
11. Fujita S, Senda Y, Okusi T, et al. Catheter-related fungemia due to fl uconazole-resistant Candida nivariensis. J Clin Microbiol 2007; 45: 3459-3461.
12. Lockhart SR, Messer SA, Gherna M, et al. Identifi cation of C andida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: Comparison to the literature. J Clin Microbiol 2009; 47: 1216-1217.
13. Marr KA. The changing spectrum of candidemia in oncology patients: Therapeutic implications. Curr Opin Infect Dis 2000; 13: 615-620.
14. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: Evolution of risk factors after the adoption of prophylactic fl uconazole. J Infect Dis 2000; 181: 309-316.
15. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011; 11: 142-151.
16. De Rosa FG, Garazzino S, Pasero D, Di Perri G, Ranieri VM. Invasive candidiasis and candidemia: New guidelines. Minerva Anestesiol 2009; 75: 453-458.
17. Maertens J, Marchetti O, Herbrecht R, et a l. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Pummary of the ECIL 3-2009 update. Bone Marrow Transplant 2011; 46: 709-718.
18. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-535.
19. Loiez C, Wallet F, Sendid B, Courcol RJ. Evaluation of VITEK 2 colorimetric cards versus fl uorimetric cards for identifi cation of yeasts. Diagn Microbiol Infect Dis 2006; 56: 455-457.
20. Pincus DH, Orenga S, Chatellier S. Yeast identifi cationYpast, present, and future methods. Med Mycol 2007; 45: 97-121.
21. Borman AM, Petch R, Linton CJ, et al. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol 2008; 46: 933-938.
22. Sullivan DJ, Westerneng TJ, Haynes KA, Bennett DE, Coleman DC. Candida dubliniensis sp. nov.: Phenotypic and molecular characterization of a novel species associated with oral candidosis in HIV-infected individuals. Microbiology 1995; 141: 1507-1521.
23. Garner CD, Starr JK, McDonough PL, Altier C. Molecular identifi cation of veterinary yeast isolates by use of sequence-based analysis of the D1/D2 region of the large ribosomal subunit. J Clin Microbiol 2010; 48: 2140-2146.
24. Leaw SN, Chang HC, Sun HF, et al. Identifi cation of medically important yeast species by sequence analysis of the internal transcribed spacer regions. J Clin Microbiol 2006; 44: 693-699.
25. Cornet M, Sendid B, Fradin C, et al. Molecular identifi cation of closely related Candida species using two ribosomal intergenic spacer fi ngerprinting methods. J Mol Diagn 2011; 13: 12-22.
26. Bader O, Weig M, Taverne-Ghadwal L, et al. Improved clinical laboratory identifi cation of human pathogenic yeasts by matrix-assisted laser desorption ionization time-of-fl ight mass spectrometry. Clin Microbiol Infect 2011; 17: 1359-1365.
27. Bizzini A, Durussel C, Bille J, Greub G, Prod ' hom G. Performance of matrix-assisted laser desorption ionization-time of fl ight mass spectrometry for identifi cation of bacterial strains routinely isolated in a clinical microbiology laboratory. J Clin Microbiol 2010; 48: 1549-1554.
28. Croxatto A, Prod ' hom G, Greub G. Applications of MALDI-TOF mass spectrometry in clinical diagnostic microbiology. FEMS Microbiol Rev 2012; 36: 380-407.
29. Dhiman N, Hall L, Wohlfi el SL, Buckwalter SP, Wengenack NL. Performance and cost analysis of matrix-assisted laser desorption ionization-time of fl ight mass spectrometry for routine identifi cation of yeast. J Clin Microbiol 2011; 49: 1614-1616.
30. Pinto A, Halliday C, Zahra M, et al. Matrix-assisted laser desorption ionization-time of fl ight mass spectrometry identifi cation of yeasts is contingent on robust reference spectra. PLoS One 2011; 6: E25712.
31. Putignani L, Del Chierico F, Onori M, et al. MALDI-TOF mass spectrometry proteomic phenotyping of clinically relevant fungi. Mol Biosyst 2011; 7: 620-629.
32. Stevenson LG, Drake SK, Shea YR, Zelazny AM, Murray PR. Evaluation of matrix-assisted laser desorption ionization-time of fl ight mass spectrometry for identifi cation of clinically important yeast species. J Clin Microbiol 2010; 48: 3482-3486.
33. van Veen SQ, Claas EC, Kuijper EJ. High-throughput identifi cation of bacteria and yeast by matrix-assisted laser desorption ionization-time of fl ight mass spectrometry in conventional medical microbiology laboratories. J Clin Microbiol 2010; 48: 900-907.
34. Alanio A, Beretti JL, Dauphin B, et al. Matrix-assisted laser desorption ionization time-of-fl ight mass spectrometry for fast and accurate identifi cation of clinically relevant Aspergillus species. Clin microbiol Infect 2011; 17: 750-755.
35. Marklein G, Josten M, Klanke U, et a l. Matrix-assisted laser desorption ionization-time of fl ight mass spectrometry for fast and reliable identifi cation of clinical yeast isolates. J Clin Microbiol 2009; 47: 2912-2917.
36. Lott TJ, Kuykendall RJ, Reiss E. Nucleotide sequence analysis of the 5.8S rDNA and adjacent ITS2 region of Candida albicans and related species. Yeast 1993; 9: 1199-1206.
37. Kaleta EJ, Clark AE, Cherkaoui A, et a l. Comparative analysis of PCR-electrospray ionization/mass spectrometry [MS] and MALDITOF/ MS for the identifi cation of bacteria and yeast from positive blood culture bottles. Clin Chem 2011; 57: 1057-1067.
38. Schubert S, Weinert K, Wagner C, et a l. Novel, improved sample preparation for rapid, direct identifi cation from positive blood cultures using matrix-assisted laser desorption/ionization time-of-fl ight [MALDITOF] mass spectrometry. J Mol Diagn 2011; 13: 701-706.
39. Seyfarth F, Wiegand C, Erhard M, et al. Identifi cation of yeast isolated from dermatological patients by MALDI-TOF mass spectrometry. Mycoses 2012; 55: 276-280.
40. Van Herendael BH, Bruynseels P, Bensaid M, et al. Validation of a modifi ed algorithm for the identifi cation of yeast isolates using matrix-assisted laser desorption/ionisation time-of-fl ight mass spectrometry [MALDI-TOF MS]. Eur J Clin Microbiol Infect Dis 2012; 31: 841-848.
41. Marinach-Patrice C, Fekkar A, Atanasova R, et al. Rapid species diagnosis for invasive candidiasis using mass spectrometry. PLoS One 2010; 5: E8862.
42. Marinach C, Alanio A, Palous M, et a l. MALDI-TOF MS-based drug susceptibility testing of pathogens: The example of Candida albicans and fl uconazole. Proteomics 2009; 9: 4627-4631.
43. Qian J, Cutler JE, Cole RB, Cai Y. MALDI-TOF mass signatures for differentiation of yeast species, strain grouping and monitoring of morphogenesis markers. Anal Bioanal Chem 2008; 392: 439-449.
44. Hettick JM, Green BJ, Buskirk AD, et a l. Discrimination of A spergillus isolates at the species and strain level by matrix-assisted laser desorption/ionization time-of-fl ight mass spectrometry fi ngerprinting. Anal Biochem 2008; 380: 276-281.
45. Theel ES, Hall L, Mandrekar J, Wengenack NL. Dermatophyte identifi cation using matrix-assisted laser desorption ionization-time of fl ight mass spectrometry. J Clin Microbiol 2011; 49: 4067-4071.
46. Kemptner J, Marchetti-Deschmann M, Mach R, et al. Evaluation of matrix-assisted laser desorption/ionization [MALDI] preparation techniques for surface characterization of intact Fusarium spores by MALDI linear time-of-fl ight mass spectrometry. Rapid Commun Mass Spectrom 2009; 23: 877-884.
47. Seyfarth F, Ziemer M, Sayer HG, et al. The use of ITS DNA sequence analysis and MALDI-TOF mass spectrometry in diagnosing an infection with Fusarium proliferatum. Exp Dermatol 2008; 17: 965-971.
48. Rogers PD, Vermitsky JP, Edlind TD, Hilliard GM. Proteomic analysis of experimentally induced azole resistance in Candida glabrata. J Antimicrob Chemother 2006; 58: 434-438.